The FDA approved DAYBUE STIX, a powder formulation of trofinetide, for the treatment of Rett syndrome in adults and pediatric patients two years and older. Acadia Pharmaceuticals said the formulation is dye‑ and preservative‑free and delivers the same efficacy and safety profile as existing oral solutions. The approval gives clinicians an additional dosing option and may improve administration convenience for some patients. Acadia indicated the new product will broaden access and support treatment continuity for families managing this rare neurodevelopmental disorder.